Want to see CMMB full AI Analyst Report?
CMMB Stock Chart & Stats
$1.36
$0.04(2.94%)
At close: 4:00 PM EDT
$1.36
$0.04(2.94%)
Day’s Range― - ―
52-Week Range$1.35 - $4.12
Previous CloseN/A
Volume17.83K
Average Volume (3M)207.96K
Market Cap
$13.75M
Enterprise Value$4.48
Total Cash (Recent Filing)$8.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,192,266
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside267.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt materially lowers bankruptcy and interest-rate exposure for a clinical‑stage biotech, preserving flexibility to pursue trials or partner deals over the next 2–6 months. This structural balance‑sheet strength makes capital raises less urgent and improves negotiating leverage with potential collaborators.
Improving Cash‑burn And Loss TrendsA demonstrable reduction in annual cash burn signals stronger expense discipline and program prioritization, extending runway and lowering near‑term financing frequency. Sustained burn improvement supports clearer planning for trials and partnering discussions and reduces execution risk over coming quarters.
Merger With Scipher Expands Runway And Strategic CapabilitiesThe announced stock‑for‑stock merger and committed financing is a structural change that materially extends cash runway and adds precision‑medicine revenue and AI capabilities. Combining nebokitug with Scipher’s PrismRA platform diversifies near‑term commercial pathways and strengthens partnering and trial‑design prospects.
Bears Say
Pre‑revenue With Persistent Operating LossesAbsence of product sales means the company cannot self‑fund operations; recurring operating losses reflect ongoing R&D spend without offsetting revenues. This structural revenue gap forces continuous capital access reliance and raises the bar for milestones that must be achieved to become cash‑generative.
Ongoing Reliance On External Financing And Dilution RiskSustained negative cash flow and lack of commercial revenue create recurring financing dependency. Over time this typically results in equity issuances or dilutive deals; declining equity and negative ROE magnify stakeholder dilution risk and can compress strategic optionality if capital markets tighten.
Small Organizational Scale Limits Execution CapacityA very small headcount constrains internal capability to run concurrent late‑stage trials, scale regulatory or commercial functions, and manage multiple partnerships. This increases reliance on external CROs and partners, elevating operational and execution risk as programs progress toward registrational work.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $1.35 and its highest was $4.12 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $13.75M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Nov 06, 2026 which is in 81 days.
How were Chemomab Therapeutics’s earnings last quarter?
Currently, no data Available
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,192,266 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
CMMB Stock 12 Month Forecast
Average Price Target
$5.00
▲(267.65% Upside)